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a  b  s  t  r  a  c  t
Anti-tumor necrosis factor drugs are frequently preferred in the treatment of rheumatologic
diseases and other inﬂammatory diseases. The development of myositis after using anti-
tumor necrosis factor drugs is a rare clinical condition. Here we aimed to report cases who
developed myositis after using anti-tumor necrosis factor drugs and review the current
literature. We  report two cases of rheumatoid arthritis and a case of ankylosing spondylitis
developed idiopathic inﬂammatory myopathy following anti-tumor necrosis factor therapy.
In  conclusion, myositis could develop during anti-tumor necrosis factor therapy, so these
patients should be evaluated carefully initially for myositis and should be closely monitored
due  to the potential for developing myositis in treatment process.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Três  casos  de  miosite  induzida  pelo  anti-TNF  e  revisão  da  literatura
alavras-chave:
ármacos antifator de necrose
umoral (anti-TNF)
iosite
o-1
r  e  s  u  m  o
Os fármacos antifator de necrose tumoral (anti-TNF) são frequentemente preferidos no
tratamento de doenc¸as reumatológicas e outras doenc¸as inﬂamatórias. O desenvolvimento
de  miosite após o uso de anti-FNT é uma condic¸ão clínica rara. Este estudo objetivou descr-
ever  casos de pacientes que desenvolveram miosite após o uso de anti-TNF e fazer uma
revisão da literatura atual. Descrevem-se dois casos de artrite reumatoide (AR) e um caso de
espondilite anquilosante (EA) que desenvolveram miopatia inﬂamatória idiopática após o
tratamento com anti-TNF. Em conclusão, pode haver desenvolvimento de miosite durante otratamento com anti-TNF, de modo que esses pacientes devem ser cuidadosamente avalia-Please cite this article in press as: Zengin O, et al. Three cases of anti-TN
http://dx.doi.org/10.1016/j.rbre.2016.05.003
dos  inicialmente à procur
do  potencial de desenvolv
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a de miosite e devem ser cuidadosamente monitorados em razão
imento de miosite no processo de tratamento.
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Introduction
Tumor necrosis factor alpha (TNF-)  is a proinﬂammatory
cytokine that plays an important role in the pathogenesis
of RA, AS and many  other inﬂammatory diseases. Due to
its role in the inﬂammatory process, anti-TNF drugs are fre-
quently preferred in the treatment of rheumatologic diseases
and other inﬂammatory diseases.1
Although anti-TNF drugs generally demonstrate their
anti-inﬂammatory effects by antagonizing TNF-, they have
different effects on the immune system and inﬂammation
depending on their chemical structures and physiological
characteristics. This different efﬁcacy determines both the
clinical indications and side effect proﬁle of the drugs.
The main side effects of the drugs are predisposition to
infections, allergic reactions, malignancies, demyelinating
diseases, congestive heart failure, bone marrow depression,
and autoimmune diseases.2 The development of myositis
after using anti-TNF is a rare clinical condition.3 We aimed
to present three cases followed up with the diagnosis of AS
and RA which developed myositis after using anti-TNF.
Case  1
A 30-year-old male patient had been followed-up with the
diagnosis of AS for ten years. He had been taking non-steroidal
anti-inﬂammatory drugs (NSAID) for 10 years. Etanercept
25 mg  2 times a week was initiated as his complaints have
increased. The patient had taken a total of 20 (2.5 months)
doses of etanercept treatment and the patient had complaints
of weakness, fatigue and difﬁculty in climbing the stairs
within the last three weeks. Upon his physical examination
there was weakness in proximal muscles of upper and lower
extremities, yet no dermatological involvement was found.
Aspartate aminotransferase (AST), alanine aminotransferase
(ALT), creatinine kinase (CK) and lactate dehydrogenase (LDH)
were 536 U/L, 535 U/L, 6035 U/L, and 739 U/L, respectively. Thy-
roid stimulating hormone (TSH) and other biochemical tests
were normal. ANA was 1/160 positive, anti Jo-1 was pos-
itive, and anti dsDNA, anti-SSA, anti-RNP were negative.
Electromyography (EMG) ﬁndings revealed myopathy in prox-
imal muscles. The deltoid muscle biopsy was consistent
with polymyositis. Etanercept was stopped and three-day
pulse steroid (1 g) treatment was started with the diagnosis
of inﬂammatory myositis, and subsequently 1 g cyclophos-
phamide/month treatment was started. At the ﬁrst month
of treatment, CK, AST, ALT and LDH levels decreased. The
steroid dose was gradually decreased and stopped. Cyclophos-
phamide treatment continued for one year and at the end of
one year, the patient was started to be followed up with only
NSAIDs.
Case  2Please cite this article in press as: Zengin O, et al. Three cases of anti-TN
http://dx.doi.org/10.1016/j.rbre.2016.05.003
A 20-year-old female patient had been followed-up with the
diagnosis of RA for two years. Adalimumab had been started
to the patient who had methotrexate resistance. Follow-
ing adalimumab treatment, the complaints related to joints 1 6;x  x x(x x):xxx–xxx
completely had regressed and in the sixth month of treat-
ment, the patient had the complaints of weakness, fatigue,
pain in the arms and legs, and difﬁculty climbing the stairs,
which had gradually increased within the last two  weeks.
Upon physical examination, there was weakness in the upper-
lower extremities. There was no dermatological involvement
in the patient. AST, ALT, CK, and LDH were 1024 U/L, 307 U/L,
4772 U/L, and 1701 U/L, respectively. TSH and other biochem-
ical tests were normal. ANA (titer 1/320) and anti Jo-1 was
positive. Anti-SSA, anti-RNP, c-ANCA, and p-ANCA were nega-
tive. EMG ﬁndings revealed myopathy in the proximal muscles.
The deltoid muscle biopsy was consistent with myositis. Adal-
imumab treatment stopped. Three days pulse steroid (1 g)
treatment was administered with the diagnosis of PM.  Adali-
mumab was switched to rituximab. Following the treatment,
CK levels rapidly decreased. In the second month following
the treatment, the steroid dose was decreased up to 5 mg/day.
On the control in the 16th month, there were no complaints
and the patient is currently being followed-up with rituximab
and methotrexate.
Case  3
A 44-year-old female had been followed-up with the diag-
nosis of RA for approximately seven years. The patient had
been using adalimumab 40 mg/2 weeks for three years. Fol-
lowing adalimumab treatment, all complaints related to the
joints had decreased. However, the patient had the complaints
of eruption in the arms, forehead, and around the nose, on
the metacarpophlangeal joints of hand, fatigue, difﬁculty in
climbing the stairs and dyspnea, which increased with effort
within last four weeks. Upon her physical examination, there
was weakness in proximal muscles of all extremities and erup-
tions consistent with erythema on the arms. There was no
arthritis or joint deformity. Clinical evaluation showed dif-
fuse pulmonary crackles. Sedimentation rate was 40 mm/h
(5–20), and C-reactive protein (CRP) was 45 mg/L (0–5). AST was
169 U/L, CK was 1563 U/L. ANA was in 1/320 homogenous pat-
tern and anti-Jo-1 was positive. Anti-SSA, anti-RNP, c-ANCA,
and anti-dsDNA were negative. There was bilateral inﬁltra-
tion in chest radiography. Thorax HRCT was consistent with
interstitial lung disease. EMG testing conﬁrmed the presence
of proximal myopathy. Muscle biopsy was consistent with
myositis. All these ﬁndings suggested TNF-induced dermato-
myositis and interstitial lung involvement. Three-day pulse
steroid (1 g) treatment initially started followed 1 g cyclophos-
phamide and rituximab treatments. Following the treatment,
serum CK levels rapidly decreased. In the ﬁrst month follow-
ing the treatment biochemical tests decreased. However, there
was partial improvement in dyspnea. The patient is in the 8th
month after the treatment, the patient’s symptoms related to
interstitial lung disease continue.
MethodsF induced myositis and literature review. Rev Bras Reumatol. 2016.
Pubmed was searched from 2003 present using the terms:
“TNF-, anti-TNF-”, “dermatomyositis”, “polymyositis”,
“inﬂammatory myopathy”, “etanercept”, “lenercept”, “inﬂix-
imab”, “adalimumab”, “golimumab”, “certolizumab”. Full
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ext articles in the English language were selected. Then
he following co-indexing terms were used: “pathogenesis”,
pathophysiology”, “treatment” or “therapy”. We didn’t con-
ider congress abstracts or unpublished results. We  included
ll cases where a clear baseline diagnosis was made and the
nset of DM/PM was recorded after the use of anti-TNF-
gents.
iscussion
e  presented two cases of RA and a case of AS which devel-
ped PM and DM following anti-TNF use. There was prominent
linical improvement in the two patients; however, in one
atient who developed DM,  although the clinical ﬁndings of
yositis regressed, there was partial improvement in pul-
onary ﬁndings.
Total 21 patients have been reported who myositis devel-
ped associated with anti-TNF in previous studies in the
iterature (Table 1).4–17 With the addition of our cases, at
he total 24 patients, 5 male and 14 were female. 5 patients
ere not identiﬁed gender. The mean age of patients was
383 ± 1119. There were 19 patients with RA, 2 patients with
S, 1 patient with seronegative arthritis, 1 patient with Crohn’s
isease and 1 patient with juvenile idiopathic arthritis. The
uration of the primary disease in most patients was sub-
tantially longer. 12 of the patients developed polymyositis
nd other 12 with dermatomyositis. 4 patients did not receive
MARDs (disease-modifying anti-rheumatic drugs). Most of
he patients were receiving methotrexate as DMARD (11
atients). 10 patients etanercept, 6 patients inﬁliximab, 5
atients adalimumab and 2 patients were using lenarcept.
0 patients had pulmonary involvement. ANA in 18 patients,
nti-jo1 in 7 patients, anti-PM-Scl in 1 patient, anti-dsDNA in 1
atient, anti-PL-7 in 1 patient, anti-PL-12 in 1 patient, anti-U1
NP in 1 patient were found positive.
Corticosteroid treatment was given to all patients. Pulse
teroid to 6 patients, high doses of steroids to 5 patients were
iven. The majority of patients had a response to treatment.
nly 2 patients had a partial response to treatment. There-
ore, steroid therapy seems successful in myositis induced
ith TNF therapy. After TNF blockade, duration of myositis
evelopment ranges from 2 weeks to 2 years in all patients.
he most common autoantibodies in patients were ANA and
nti-jo-1 antibody.
Anti Jo-1 (histidyl-tRNA synthetase) is a myositis speciﬁc
uto-antibody that is most frequently positive in idiopathic
nﬂammatory myopathies (PM and DM). Although it is posi-
ive at a rate of 20–30% in PM,  it becomes positive at a rate of
0–70% in patients with PM developing interstitial pulmonary
brosis.18 In polymyositis, MHC  I expression increases in mus-
le that injured as a result of an unknown cause, such as
iral infection, mechanical trauma, or ischemic injury. Finally,
oluble Jo-1 emerges. By CD4+ and CD8+ cell activation with
oluble Jo-1, both humoral and cellular immune response are
ctivated and this could cause muscle damage.19Please cite this article in press as: Zengin O, et al. Three cases of anti-TN
http://dx.doi.org/10.1016/j.rbre.2016.05.003
The current treatment strategy for patients with immune-
ediated inﬂammatory myopathies involves ﬁrst-line treat-
ent with corticosteroids, alone or in combination with
n immunosupressant such as methotrexate, azothioprine 6;x  x x(x x):xxx–xxx 3
or mycophenolate, and in more  resistant cases intravenous
immunoglobulin or biological therapy.20 Anecdotal reports
have suggested that anti-TNF-  agents (i.e.: inﬂiximab, etan-
ercept, adalimumab) may be helpful in the therapy of patients
with active refractory PM/DM.21 All the clinical trials done
to evaluate TNF- antagonists used an uncontrolled open-
label design. Conﬂicting results were obtained with both
the monoclonal antibody inﬂiximab and the soluble recep-
tor etanercept.22 Although, more  recent open-label studies
demonstrate that anti-TNF- agents clearly show no beneﬁt
in PM/DM.21
Different side effects could develop depending on the use
of anti-TNF drugs. Autoimmune diseases associated with anti-
TNF use is one of the possible side effects. The most commonly
observed autoimmune diseases are vasculitic syndromes,
lupus-like syndrome, psoriatic skin lesions, interstitial lung
diseases, sarcoidosis, autoimmune hepatitis, uveitis, and
antiphospholipid syndrome.4,7,8,10,11,15,17,18,23 Of these, lupus
and vasculitis are the most common, together comprising
60% of documented cases of anti-TNF induced autoimmune
disease.11 Anti-TNF induced dermatomyositis, however, is
rare, constituting less than one percent of reported cases of
anti-TNF induced autoimmunity. In the previous studies and
case series, anti-TNF treatment has been shown to increase
muscle weakness and exacerbate the disease.24 Moreover, the
incidence of ANA-positivity increases threefold with anti-TNF
therapy, even in the absence of a lupus-like syndrome. One of
the auto-immune clinical conditions developing secondary to
anti-TNF use is the autoantibody positivity. The most common
autoimmune antibody positivity are ANA and anti-dsDNA.
Although autoantibody development is observed with all anti-
TNF agents, it is reported to be more  frequent with inﬂiximab
use.25 ANA positivity and Jo-1 antibody positivity before anti-
TNF use in the two patients with RA presented in the current
case report were previously known. Thus, ANA positivity and
Jo-1 antibody positivity were not due to anti-TNF use. However,
autoantibodies in the patient with AS had not been evaluated
before anti-TNF use. We  retrieved all publications and add our
3 cases describing the new onset of DM/PM after anti-TNF ther-
apy (24 patients total); ANA positivity was 33% (8 cases) and
Jo-1 positivity was 20.3% (5 cases). In our opinion ANA and
Jo-1 positivity initially is not a contraindication for anti-TNF
therapy alone. However, these patients should be evaluated
carefully initially for myositis and should be closely moni-
tored due to the potential for developing myositis in treatment
process.
In our case series; PM or DM developed in patients who
used anti-TNF therapy. Patients have not got any clinical ﬁnd-
ings associated with myositis before anti-TNF therapy. Two
patients had inﬂammatory arthritis for several years and was
thought to be associated with RA. Inﬂammatory arthritis may
occur also in the myositis. Therefore, it is the difﬁcult to deter-
mine whether myositis is an early symptom of arthritis or
due to another disease in our two patients. Our patient with
AS have axial involvement, so it is easy to distinguish from
myositis. Therefore, it is easier to associate the anti-TNF treat-F induced myositis and literature review. Rev Bras Reumatol. 2016.
ment with myositis in this patient. However, if myositis had
been due to arthritis from the beginning, it is expected that the
complaints of patients should increase rapidly in patients with
RA. However, initially our patients showed clinically response
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Table 1 – The clinical and laboratory characteristics of cases developing myositis after anti-TNF use.
Primary
diagnosis/duration
Dmards Anti-TNF/duration Clinic Pul. invol. Treatment Treatment
Outcome
Antibodies
Case 1
30/m
AS
10y
No  Etanercept
2.5 m
PM  (−) MP pulse (1.0 g) Improvement ANA1:160
Jo-1Anti Jo-1
Case 2
20/f
RA
2y
Mtx  Adalimumab
6 m
PM  (−) MP pulse (1.0 g) Improvement ANA1:320
Jo-1Anti Jo-1
Case 3
44/f
RA
7y
Mtx  Adalimumab
36 m
DM  (+) MP pulse (1.0 g),
CY
Partial response ANA 1:320
Jo-1Anti Jo-1
Musial 2003 [4]
52/f
RA
20y
Mtx  Inﬂiximab
30 m
PM  (+) MP pulse (1.0 g) Improvement ANA 1:320
AntidsDNA1:20
Jo-1Anti Jo-1
Flendrie 2003 [5]a RAa  a a PM a a  a  a
Flendrie 2005 [6]
52/f
RAa  a Lenercepta DM a a Improvement a
Urata 2006 [7]
52/f
RA
33y
Mtx  Inﬂiximab
9 m
PM  (+) 30 mg MP Improvement ANA 1:640
Jo-1Anti Jo-1
Hall 2006 [8]
44/f
RA
1y
Mtx
Hcq
Etanercept
6  m
DM  (+) High dose MP,
AZP, MTX
Improvement ANA1:640
Jo-1Anti Jo-1
Liozon 2007 [9]
42/f
RA
1.5y
Mtx
Hcq
Etanercept
9  m
PM  (+) High dose MP, CY Improvement ANA 1:2560
Anti-PM-Scl
Kiltz 2008 [10]
57/f
RA
26y
Mtx
Hcq
Etanercept
30  m
PM  (+) High dose MP, CY Improvement ANA 1:2560
Kiltz 2008 [10]
46/m
AS
17y
a Inﬂiximab
6 m
PM  (−) a Improvement No
Ramos-Casals
2008 [11]
4 patients
RAa  a Inﬂiximab (2p)
Etanercept lenercept
PM (2p)
DM (2p)
a a  a  a
Brunasso 2010 [12]
45/f
RA
13y
No  Adalimumab
34 m
DM  (−) MP Improvement ANA 1:320
Klein 2010 [13]
33/f
RAa No Etanercept
5 m
DM  (+) MP Improvement No
Klein 2010 [13]
40/f
RAa No Etanercept
2y
DM  (−) MP Partial response ANA
Klein 2010 [13]
29/f
SNAa Mtx Adalimumab
3 m
DM  (−) MP, Mtx, AZP,
quinacrine
Improvement ANA 1:640
Ishiguro 2010 [14]
52/m
RA
12y
Mtx,
Buc,Tac
Etanercept
26  m
DM  (+) MP pulse (1.0 g) Improvement Anti-PL-7
Ishikawa 2010 [3]
58/f
RA
2y
Buc,Tac  Etanercept
2 m
PM  (+) MP pulse (0.5 g) Improvement ANA 1:320
Jo-1Anti Jo-1
Ishikawa 2011 [15]
63/f
RA
6m
Buc,Tac  Etanercept
2 m
PM  (+) PSL 1 mg/kg Improvement ANA 1:160
Anti-PL-12
Please cite this article in press as: Zengin O, et al. Three cases of anti-TN
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after the anti-TNF therapy. The pattern of arthritis, deformity
and erosion will help to the differential diagnosis.
Another possibility is the overlap syndrome. Inﬂammatory
myositis could be observed as a part of overlap syndrome with
other rheumatologic diseases. Myositis most frequently over-
laps with RA, systemic lupus erythematosus and scleroderma.
Aranbicia Aguila et al.26 reviewed 220 cases with inﬂammatory
myositis in terms of overlap syndrome. They found overlap
syndrome in 31 patients (9 DM, 22 PM); however, systemic
sclerosis was detected in 15 patients, SLE was detected in nine
patients and RA was detected in seven patients. Myositis rarely
overlaps with other connective tissue diseases but the exact
incidence is not known.
TNF- is a cytokine produced mainly by activated
macrophages and T-lymphocytes. It is an essential pro-
inﬂammatory mediator and is implicated in the patho-
genesis of multiple immune-mediated inﬂammatory disor-
ders, including inﬂammatory myopathies. There is growing
evidence that excessive production of pro-inﬂammatory
cytokines, and in particular TNF-, may be involved in the
pathogenesis of idiopathic inﬂammatory myopathies.27 TNF-
 and its receptors are increased in myositis. Suggesting a role
in this disease and may be used in therapy but on the con-
trary, it was observed that treatment of anti-TNF may rise the
exacerbate. The reason for this is not fully understood. Two
possible causes have been suggested. Firstly, according to the
cytokine-shift hypothesis; TNF- inhibition will change the
balance in cytokine production as T helper-1 and T helper-2
and promotes the type 1 interferon production. Type-1 inter-
feron has been shown to be increased and the play role in
the pathogenesis in patients with myositis. The second pos-
sible cause is increase the production of autoantibodies with
the TNF blockade interfere to apoptosis. For example, after
the TNF blockade in patients with RA, ANA and anti-ds DNA
antibodies increased that is known.13
TNF inhibitors are important drugs used in the treatment of
autoinﬂammatory diseases. They can rarely induce the devel-
opment of myositis besides the known their side effects such
as infections, congestive heart failure, demyelinating diseases
and autoimmune diseases. When complaints arise such as
shortness of breath, muscle weakness and skin rash, patients
who take TNF treatment should be evaluated for myositis.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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